highest PSAprostate cancermetastasisyoungIntroduction: Prostate cancer is the sixth most common cancer in the world, the second most common cancer among men, and the most common cancer in men in Europe. Metastatic prostate cancer among young patients represents the rarest of the newly diagnosed ...
Prostate-specific antigen (PSA) is well known as a specific tumor marker for prostate cancer, but carcinoembryonic antigen (CEA)- and carbohydrate antigen 19-9 (CA19-9)-elevating adenocarcinomas originating in the prostate gland are rare. We report a case of metastatic adenocarcinoma of the prost...
Serum prostate-specific antigen (PSA) levels were studied in the EORTC trial of zoladex plus flutamide versus orchidectomy in metastatic prostatic cancer. Forty-four of 60 patients had a decrease of PSA to less than or equal to 10 ng/ml at 3 to 6 months after treatment. The combination of...
The Clinical Usefulness of Serum Prostate Specific Antigen After Hormonal Therapy of Metastatic Prostate Cancerprostatic neoplasmsantigensdifferentiationorchiectomyhormone antagonistsWe longitudinally followed serum prostate specific antigen (PSA) levels in 48 patients who were treated with either orchiectomy, ...
However, after the initial response, almost all patients will eventually progress despite the low levels of testosterone. Disease at this stage is termed castration resistant prostate cancer (CRPC). Before 2010, the taxane docetaxel was the first and only life prolonging agent for metastatic CRPC ...
Overall, 20% of the patients treated reached the primary endpoint — undetectable prostate-specific antigen (PSA) and noncastrate levels of testosterone at 20 months, which the authors described as "no evidence of disease" (NED). This endpoint "could not have been achieved with any single thera...
Evidence-based radiation oncology: Definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer The standard treatment options based on the risk category (stage, Gleason score, PSA) for localized prostate cancer include surgery, radiotherapy and watch... BA Jereczek-Fossa,R Orecchia...
Viviana Frantellizzi, Radiology and Oncology, 2019 Metastatic Prostate Cancer with Highest Reported PSA Level Martha Orsolya, Acta Medica Marisiensis, 2016 Discovery of C19-9 as a novel non-RGD inhibitor of αvβ3 to overcome enzalutamide resistance in castration-resistant prostate canc...
Assessment of response to therapy in prostate cancer (PCa) patients relies on a combination of clinical parameters, the biochemical response as reflected by a change in serum prostate-specific antigen (PSA) levels, and on the morphological assessment on computerized tomographic (CT) imaging using the...
Abiraterone (AA) is indicated in mRCPC (metastatic castration-resistant prostate cancer) before or after chemotherapy, and in mHSPC (metastatic hormone-sensitive prostate cancer) as first line. A decrease in PSA is associated with improved clinical response and increased survival. Recent studies have...